Why is Abbott commercializing Freenome’s FDA-approved SimpleScreen CRC test in the U.S.?

The article says the FDA approved Freenome’s blood-based colorectal cancer test, SimpleScreen CRC, and Abbott received exclusive U.S. marketing rights. The key angle is that Abbott’s scale and channel access could matter more than the approval itself, shifting attention to launch execution, physician adoption, payer coverage, and uptake.